Cargando…

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial

BACKGROUND: The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ(9)-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex(®)) can dec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trigo, Jose M., Soliman, Alexandra, Quilty, Lena C., Fischer, Benedikt, Rehm, Jürgen, Selby, Peter, Barnes, Allan J., Huestis, Marilyn A., George, Tony P., Streiner, David L., Staios, Gregory, Le Foll, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791962/ https://www.ncbi.nlm.nih.gov/pubmed/29385147 http://dx.doi.org/10.1371/journal.pone.0190768

Ejemplares similares

Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
por: Mills, Llewellyn, et al.
Publicado: (2022)

Circulating Endocannabinoids and N-Acylethanolamines in Individuals with Cannabis Use Disorder—Preliminary Findings
por: Boachie, Nadia, et al.
Publicado: (2023)

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol
por: Bhardwaj, Anjali K., et al.
Publicado: (2018)

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis
por: Wilsey, Barth L, et al.
Publicado: (2016)

Monitoring the impact of cannabis use
por: Le Foll, Bernard
Publicado: (2022)

Implementation and Preliminary Evaluation of a 12-Week Cognitive Behavioural and Motivational Enhancement Group Therapy for Cannabis Use Disorder
por: Trick, Leanne, et al.
Publicado: (2023)

12-month follow-up of an exploratory ‘brief intervention’ for high-frequency cannabis users among Canadian university students
por: Fischer, Benedikt, et al.
Publicado: (2012)

Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity
por: Gajofatto, Alberto, et al.
Publicado: (2023)

The Devil Is in the Details! On Regulating Cannabis Use in Canada Based on Public Health Criteria: Comment on "Legalizing and Regulating Marijuana in Canada: Review of Potential Economic, Social, and Health Impacts"
por: Rehm, Jürgen, et al.
Publicado: (2016)

Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
por: Matheson, Justin, et al.
Publicado: (2020)

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders
por: Andrews, Christopher N, et al.
Publicado: (2019)

Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
por: Pau, Massimiliano, et al.
Publicado: (2022)

Psychosocial and pharmacological interventions for the treatment of cannabis use disorder
por: Sabioni, Pamela, et al.
Publicado: (2018)

Urinary Acrylonitrile Metabolite Concentrations Before and after Smoked, Vaporized, and Oral Cannabis in Frequent and Occasional Cannabis Users
por: Ashley, David L., et al.
Publicado: (2020)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
por: Schwittay, Maximilian A., et al.
Publicado: (2021)

Correlation of Nabiximols Dose to Steady-State Concentrations of Cannabinoids in Urine Samples from Patients with Multiple Sclerosis
por: Birke, Rüdiger, et al.
Publicado: (2022)

Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study
por: Rosa, Gian Marco, et al.
Publicado: (2022)

Clinical management of cannabis withdrawal
por: Connor, Jason P., et al.
Publicado: (2022)

Cannabis Use and Car Crashes: A Review
por: Preuss, Ulrich W., et al.
Publicado: (2021)

Impacts of recreational cannabis legalization on use and harms: A narrative review of sex/gender differences
por: Matheson, Justin, et al.
Publicado: (2023)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols
por: Chisari, Clara Grazia, et al.
Publicado: (2023)

Normative Misperceptions About Cannabis Use in a Sample of Risky Cannabis Users
por: Cunningham, John A, et al.
Publicado: (2023)

A method for co-creation of an evidence-based patient workbook to address alcohol use when quitting smoking in primary care: a case study
por: Minian, Nadia, et al.
Publicado: (2018)

The impact of cannabis legalization for recreational purposes: The Canadian experience
por: Le Foll, B.
Publicado: (2023)

New Zealand's failed cannabis legalization referendum – implications for cannabis policy reform
por: Fischer, Benedikt, et al.
Publicado: (2021)

Cannabis self-administration in the human laboratory: a scoping review of ad libitum studies
por: Xiao, Ke Bin, et al.
Publicado: (2023)

Comparison of CBD and Cannabis Use Motives
por: Bilaonova, Aksinya, et al.
Publicado: (2021)

Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
por: Kanaan, Ahmad Seif, et al.
Publicado: (2017)

Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates
por: Manthey, Jakob, et al.
Publicado: (2021)

Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample
por: Rubin-Kahana, Dafna Sara, et al.
Publicado: (2022)

Metabolic Effects of Chronic Cannabis Smoking
por: Muniyappa, Ranganath, et al.
Publicado: (2013)

Transcriptional Changes Common to Human Cocaine, Cannabis and Phencyclidine Abuse
por: Lehrmann, Elin, et al.
Publicado: (2006)

Controlled administration of cannabis to mitigate cannabis-attributable harm among recreational users: a quasi-experimental study in Germany
por: Manthey, Jakob, et al.
Publicado: (2020)

Combining alcohol interventions with tobacco addictions treatment in primary care—the COMBAT study: a pragmatic cluster randomized trial
por: Minian, Nadia, et al.
Publicado: (2017)

Integrating a brief alcohol intervention with tobacco addiction treatment in primary care: qualitative study of health care practitioner perceptions
por: Minian, Nadia, et al.
Publicado: (2021)

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
por: Twelves, Chris, et al.
Publicado: (2021)

Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study
por: Samokhvalov, Andriy V., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nr4p4paud0e7ehe7qdds0qsae7